Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumify for conjunctival hyperemia in glaucoma patients on Rocklatan
NCT07209410Phase 4Recruiting
- Sponsor
- Insight Eyecare Specialties
- Start
- Nov 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of brimonidine in Conjunctival hyperemia, sponsored by Insight Eyecare Specialties. Primary endpoint: Efron Grading scale of ocular redness at 2 weeks. Started Nov 2025; status: recruiting.
02
Drugs
brimonidine
03
Conditions
Conjunctival hyperemia
Beyond the preview
Go deeper on NCT07209410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07209410.